HMHugh Myrick

Hugh Myrick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hugh Myrick has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Scott Henderson

    Ralph H. Johnson Department of Veterans Affairs Medical Center Research and Development Service Charleston, SC

    5 shared publications
  • Konstantin Voronin

    Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA

    4 shared publications
  • Robert Malcolm

    From the Ralph H. Johnson Department of Veterans Affairs Medical Center (HM, HCB), Research and Development Service, Charleston, South Carolina; and Department of Psychiatry and Behavioral Sciences, Alcohol Research Center, Medical University of South Carolina (HM, RM, PKR, EB, RFA, CLR), Charleston, South Carolina

    4 shared publications
  • Kathleen T. Brady

    3 shared publications
  • Patrick K. Randall

    From the *Ralph H. Johnson Department of Veterans Affairs Medical Center, Research and Development Service; and †Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, and ‡Center for Advanced Imaging Research, Medical University of South Carolina, Charleston, SC

    3 shared publications
  • Raymond F. Anton

    From the *Ralph H. Johnson Department of Veterans Affairs Medical Center, Research and Development Service; and †Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, and ‡Center for Advanced Imaging Research, Medical University of South Carolina, Charleston, SC

    3 shared publications

Latest Publications

  • Open Access

    Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes

    by Hildi J. Hagedorn, Jennifer P. Wisdom, Heather Gerould, Erika Pinsker, Randall Brown, Michael Dawes, Eric Dieperink, Donald Hugh Myrick, Elizabeth M. Oliva, Todd H. Wagner, et al.

    Background: Despite the high prevalence of alcohol use disorders (AUDs), in 2016, only 7.8% of individuals meeting diagnostic criteria received any type of AUD treatment. Developing options for treatment within primary care settings is imperative to increase treatment access. As part of a trial to implement AUD pharmacotherapy in primary care settings, this qualitative study analyzed pre-implementation provider interviews using the Consolidated Framework for Implementation Research (CFIR) to identify implementation barriers. Methods: Three large Veterans Health Administration facilities participated in the implementation intervention. Local providers were trained to serve as implementation/clinical champions and received external facilitation from the project team. Primary care providers received a dashboard of patients with AUD for case identification, educational materials, and access to consultation from clinical champions. Veterans with AUD diagnoses received educational information in the mail. Prior to the start of implementation activities, 24 primary care providers (5–10 per site) participated in semi-structured interviews. Transcripts were analyzed using common coding techniques for qualitative data using the CFIR codebook Innovation/Intervention Characteristics, Outer Setting, Inner Setting, and Characteristics of Individuals domains. Number and type of barriers identified were compared to quantitative changes in AUD pharmacotherapy prescribing rates. Results: Four major barriers emerged across all three sites: complexity of providing AUD pharmacotherapy in primary care, the limited compatibility of AUD treatment with existing primary care processes, providers’ limited knowledge and negative beliefs about AUD pharmacotherapy and providers’ negative attitudes toward patients with AUD. Site specific barriers included lack of relative advantage of providing AUD pharmacotherapy in primary care over current practice, complaints about the design quality and packaging of implementation intervention materials, limited priority of addressing AUD in primary care and limited available resources to implement AUD pharmacotherapy in primary care. Conclusions: CFIR constructs were useful for identifying pre-implementation barriers that informed refinements to the implementation intervention. The number and type of pre-implementation barriers identified did not demonstrate a clear relationship to the degree to which sites were able to improve AUD pharmacotherapy prescribing rate. Site-level implementation process factors such as leadership support and provider turn-over likely also interacted with pre-implementation barriers to drive implementation outcomes.


  • Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration

    by Alex H.S. Harris, Randall Brown, Michael Dawes, Eric Dieperink, Donald Hugh Myrick, Heather Gerould, Todd H. Wagner, Jennifer P. Wisdom, Hildi J. Hagedorn


  • The Use of Divalproex in the Treatment of Addictive Disorders

    by Hugh Myrick, Md, Kathleen T. Brady, Ph D

    To date, few medications have shown efficacy in the treatment of addictive disorders. The lack of effective treatments has led to the evaluation of a variety of pharmacotherapies to reduce alcohol or illicit drug use. The anticonvulsant agents are a class of medications that may represent novel treatments for addictive disorders. One of the most studied anticonvulsant agents in the treatment of addictive disorders has been valproate. This article will review the literature regarding the use of valproate in treating alcohol withdrawal symptoms and in reducing the use of alcohol and cocaine.

  • The Effect of Aripiprazole on Cue-Induced Brain Activation and Drinking Parameters in Alcoholics

    by Hugh Myrick, Xingbao Li, Patrick K. Randall, Scott Ba Henderson, Konstantin Voronin, Raymond F. Anton

    Because the effects of alcohol and its environmental cues on brain dopamine have been implicated in the maintenance of heavy drinking, drugs that modify dopamine might be useful in reducing drinking or promoting abstinence. The goal of the current study was to use an established brain imaging paradigm to explore the effect of aripiprazole (final dose 15 mg over a 14-day period), a dopamine stabilizer medication, on alcohol cue-induced brain activation and drinking in alcoholics. Non-treatment-seeking alcoholics were randomly assigned aripiprazole (n = 14) or identical placebo (n = 16) and reported their alcohol use while taking study medication for 14 days before an alcohol cue-induced brain functional magnetic resonance imaging study. In a Philips 3.0-T magnetic resonance imaging scanner, subjects were given a sip of alcohol before viewing a randomized presentation alcoholic- and nonalcoholic-beverage photographs while subjects rated their urge to drink. During photograph presentation, changes in regional brain activity were measured, and differences between viewing alcoholic beverage and nonalcoholic beverages were compared within and between groups. Brain activity analysis revealed increased activation for placebo-treated subjects in the right ventral striatum (P < 0.005; threshold 15 voxels), while there was a blunting of activation in this area in the aripiprazole-treated subjects. Aripiprazole-treated subjects, compared with placebo-treated subjects, also had significantly less heavy drinking during the 14-day medication period. The study provides both novel and valuable information regarding the effect of aripiprazole on cue-induced brain activation and voluntary drinking during treatment.


  • A Double‐Blind Trial of Gabapentin Versus Lorazepam in the Treatment of Alcohol Withdrawal

    by Hugh Myrick, Robert Malcolm, Patrick K. Randall, Elizabeth Boyle, Raymond F. Anton, Howard C. Becker, Carrie L. Randall

    Introduction:  Some anticonvulsants ameliorate signs and symptoms of alcohol withdrawal, but have an unacceptable side effect burden. Among the advantages of using anticonvulsant agents in this capacity is their purported lack of interaction with alcohol that could increase psychomotor deficits, increase cognitive impairment, or increase intoxication. The aim of this study was to evaluate alcohol use and symptom reduction of gabapentin when compared with lorazepam in the treatment of alcohol withdrawal in a double‐blinded randomized clinical trial.Methods:  One hundred individuals seeking outpatient treatment of alcohol withdrawal with Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA‐Ar) ratings ≥10 were randomized to double‐blind treatment with 2 doses of gabapentin (900 mg tapering to 600 mg or 1200 tapering to 800 mg) or lorazepam (6 mg tapering to 4 mg) for 4 days. Severity of alcohol withdrawal was measured by the CIWA‐Ar on days 1 to 4 of treatment and on days 5, 7, and 12 post‐treatment and alcohol use monitored by verbal report and breath alcohol levels.Results:  CIWA‐Ar scores decreased over time in all groups; high‐dose gabapentin was statistically superior but clinically similar to lorazepam (p = 0.009). During treatment, lorazepam‐treated participants had higher probabilities of drinking on the first day of dose decrease (day 2) and the second day off medication (day 6) compared to gabapentin‐treated participants (p = 0.0002). Post‐treatment, gabapentin‐treated participants had less probability of drinking during the follow‐up post‐treatment period (p = 0.2 for 900 mg and p = 0.3 for 1200 mg) compared to the lorazepam‐treated participants (p = 0.55). The gabapentin groups also had less craving, anxiety, and sedation compared to lorazepam.Conclusions:  Gabapentin was well tolerated and effectively diminished the symptoms of alcohol withdrawal in our population especially at the higher target dose (1200 mg) used in this study. Gabapentin reduced the probability of drinking during alcohol withdrawal and in the immediate postwithdrawal week compared to lorazepam.


  • Open Access

    Effect of Naltrexone and Ondansetron on Alcohol Cue–Induced Activation of the Ventral Striatum in Alcohol-Dependent People

    by Hugh Myrick, Raymond F. Anton, Xingbao Li, Scott Henderson, Patrick K. Randall, Konstantin Voronin

    Considerable data are available to support the use of the opiate antagonist naltrexone in the treatment of alcohol dependence.1-3 Naltrexone is approved by the US Food and Drug Administration for the treatment of alcoholism and has been shown to reduce either the priming effect or the reward (stimulation) effect of alcohol.4-8 Also, in clinical treatment studies, naltrexone has been found to enhance abstinence,9 to reduce drinks per drinking day,1,2 to reduce craving,3 and to enhance resistance (reduce urge and impulse) to drink.1,10 Unfortunately, not all studies11,12 with naltrexone have been positive. In addition, a meta-analysis of 27 randomized controlled trials of naltrexone reported that, although short-term treatment with naltrexone decreased relapse, the number of patients needed to be treated to achieve a better outcome over placebo response was 7.13 This number needed to treat for a positive effect of naltrexone over placebo was recently confirmed in a large multisite trial, the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.14 This evidence suggests that not everyone responds to treatment with naltrexone. It is not clear whether naltrexone works by blocking cue-induced reinforcement as suggested by some animal15,16 and human17,18 studies or if it works primarily by blocking alcohol's pharmacologic reward properties.4,19-21


  • A Double‐Blind Evaluation of Gabapentin on Alcohol Effects and Drinking in a Clinical Laboratory Paradigm

    by Hugh Myrick, Raymond Anton, Konstantin Voronin, Wei Wang, Scott Henderson

    Introduction: There has been increasing interest in the use of anticonvulsant agents in the treatment of alcoholism. Anticonvulsant agents have mostly been evaluated as an alternative to benzodiazepines in the treatment of alcohol withdrawal. Among the advantages of using anticonvulsant agents in this capacity is their purported lack of interaction with alcohol (i.e., interactions that could increase psychomotor deficits, cognitive impairment, and increase intoxication). This is particularly important in the treatment of alcohol withdrawal and relapse prevention in outpatients. Unfortunately, these untoward clinical interactions between anticonvulsants and alcohol in alcoholic patients have not been thoroughly assessed. The current clinical laboratory study was conducted to evaluate the safety and tolerability of the anticonvulsant gabapentin in alcoholic subjects. In addition, the ability of gabapentin to reduce alcohol craving and consumption was evaluated.Methods: Thirty‐five non‐treatment–seeking alcoholic subjects were enrolled in a subacute human laboratory study and received double‐blind treatment with up to 1,200 mg of gabapentin (n=18) or placebo (n=17) for 8 days. The safety and tolerability of gabapentin were monitored in the natural environment during the first 5 days of medication treatment and during a free‐choice limited access consumption paradigm following an initial drink of alcohol in a bar–lab setting on Day 7.Results: There was no overall effect of gabapentin on drinking or craving; however, it was tolerated (e.g., mood and sedation) as well as placebo over 5 days of natural drinking. During the bar–lab drinking session, there were no differences in subjective high or intoxication between subjects treated with gabapentin or placebo.Discussion: This study provides initial evidence that the anticonvulsant gabapentin is safe if used in conjunction with alcohol consumption in alcoholic individuals. Further study is needed with this and other lab models to determine the utility and safety of gabapentin in the treatment of alcoholism.


  • A Retrospective Chart Review Comparing Tiagabine and Benzodiazepines for the Treatment of Alcohol Withdrawal

    by Hugh Myrick, Brent Taylor, Steve LaRowe, Shaun Nguyen, Elizabeth Boyle, Kristi Cochran, Robert Malcolm

    Although benzodiazepines are the standard of care in the treatment of alcohol withdrawal, several studies have suggested that anticonvulsants may be equally effective at alleviating alcohol withdrawal symptoms and may pose less of a risk of causing rebound of symptoms which could contribute to relapse. This report compares treatment outcomes for patients (N = 13) treated for alcohol withdrawal with either the anticonvulsant tiagabine or the benzodiazepines oxazepam and lorazepam. The Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) was utilized to gauge alcohol withdrawal symptoms over the course of the study. When possible, follow-up data was obtained on alcohol use post-treatment. Both benzodiazepines and tiagabine appeared to reduce CIWA-Ar scores at about the same magnitude. There was a trend for tiagabine patients to have less postdetoxification drinking (Fisher exact test, p = 0.12). The reduction in alcohol withdrawal symptoms and decreased tendency to relapse observed in patients treated with the anticonvulsant tiagabine suggests that a double-blind, placebo controlled trial may be warranted.